A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine

Steven Black; David P. Greenberg

doi:10.1586/14760584.4.6.793

A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine

Steven Black
, David P. Greenberg

Research output: Contribution to journal › Review article › peer-review

23 Scopus citations

Abstract

Ideally, combination vaccines should not only be safe and effective, but also integrate smoothly into the vaccination schedule and provide advantages over the use of separately administered vaccines. Pentacel™ (Sanofl Pasteur Ltd., Toronto, Canada), a combination vaccine first licensed in Canada and subsequently in other countries, is immunogenic against diphtheria, tetanus, pertussis, pollo and Haemophilus influenzae type b when administered at 2, 4, 6 and 15-18 months of age. In published studies, the safety, immunogenicity and effectiveness of this combination vaccine were comparable with those of separately administered vaccines, with the advantage of a simplified dosing schedule.

Original language	English
Pages (from-to)	793-805
Number of pages	13
Journal	Expert Review of Vaccines
Volume	4
Issue number	6
DOIs	https://doi.org/10.1586/14760584.4.6.793
State	Published - 1 Dec 2005
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

DTaP
Diphtheria tetanus acellular pertussis vaccine
Haemophilus influenzae type b (Hib) vaccine
Immunizations
Inactivated poliovirus vaccine
Pentacel™
Vaccine

ASJC Scopus subject areas

Immunology
Molecular Medicine
Pharmacology
Drug Discovery

Access to Document

10.1586/14760584.4.6.793

Cite this

@article{f8804c4c5d6647d7b6a836b89ca61a3a,

title = "A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine",

abstract = "Ideally, combination vaccines should not only be safe and effective, but also integrate smoothly into the vaccination schedule and provide advantages over the use of separately administered vaccines. Pentacel{\texttrademark} (Sanofl Pasteur Ltd., Toronto, Canada), a combination vaccine first licensed in Canada and subsequently in other countries, is immunogenic against diphtheria, tetanus, pertussis, pollo and Haemophilus influenzae type b when administered at 2, 4, 6 and 15-18 months of age. In published studies, the safety, immunogenicity and effectiveness of this combination vaccine were comparable with those of separately administered vaccines, with the advantage of a simplified dosing schedule.",

keywords = "DTaP, Diphtheria tetanus acellular pertussis vaccine, Haemophilus influenzae type b (Hib) vaccine, Immunizations, Inactivated poliovirus vaccine, Pentacel{\texttrademark}, Vaccine",

author = "Steven Black and Greenberg, \{David P.\}",

note = "Funding Information: S Black has received research grant support from sanofi pasteur, Chiron, GlaxoSmithKline, MedImmune, Merck and Wyeth. DP Greenberg is a full-time employee of sanofi pasteur.",

year = "2005",

month = dec,

day = "1",

doi = "10.1586/14760584.4.6.793",

language = "English",

volume = "4",

pages = "793--805",

journal = "Expert Review of Vaccines",

issn = "1476-0584",

publisher = "Taylor and Francis Ltd.",

number = "6",

}

TY - JOUR

T1 - A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine

AU - Black, Steven

AU - Greenberg, David P.

N1 - Funding Information: S Black has received research grant support from sanofi pasteur, Chiron, GlaxoSmithKline, MedImmune, Merck and Wyeth. DP Greenberg is a full-time employee of sanofi pasteur.

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Ideally, combination vaccines should not only be safe and effective, but also integrate smoothly into the vaccination schedule and provide advantages over the use of separately administered vaccines. Pentacel™ (Sanofl Pasteur Ltd., Toronto, Canada), a combination vaccine first licensed in Canada and subsequently in other countries, is immunogenic against diphtheria, tetanus, pertussis, pollo and Haemophilus influenzae type b when administered at 2, 4, 6 and 15-18 months of age. In published studies, the safety, immunogenicity and effectiveness of this combination vaccine were comparable with those of separately administered vaccines, with the advantage of a simplified dosing schedule.

AB - Ideally, combination vaccines should not only be safe and effective, but also integrate smoothly into the vaccination schedule and provide advantages over the use of separately administered vaccines. Pentacel™ (Sanofl Pasteur Ltd., Toronto, Canada), a combination vaccine first licensed in Canada and subsequently in other countries, is immunogenic against diphtheria, tetanus, pertussis, pollo and Haemophilus influenzae type b when administered at 2, 4, 6 and 15-18 months of age. In published studies, the safety, immunogenicity and effectiveness of this combination vaccine were comparable with those of separately administered vaccines, with the advantage of a simplified dosing schedule.

KW - DTaP

KW - Diphtheria tetanus acellular pertussis vaccine

KW - Haemophilus influenzae type b (Hib) vaccine

KW - Immunizations

KW - Inactivated poliovirus vaccine

KW - Pentacel™

KW - Vaccine

UR - https://www.scopus.com/pages/publications/29944444924

U2 - 10.1586/14760584.4.6.793

DO - 10.1586/14760584.4.6.793

M3 - Review article

AN - SCOPUS:29944444924

SN - 1476-0584

VL - 4

SP - 793

EP - 805

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

IS - 6

ER -

A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this